First Time Loading...

C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 6.9 USD 0.58% Market Closed
Updated: Apr 24, 2024

Intrinsic Value

CCCC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. [ Read More ]

The intrinsic value of one CCCC stock under the Base Case scenario is 20.71 USD. Compared to the current market price of 6.9 USD, C4 Therapeutics Inc is Undervalued by 67%.

Key Points:
CCCC Intrinsic Value
Base Case
20.71 USD
Undervaluation 67%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
C4 Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CCCC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
C4 Therapeutics Inc

Provide an overview of the primary business activities
of C4 Therapeutics Inc.

What unique competitive advantages
does C4 Therapeutics Inc hold over its rivals?

What risks and challenges
does C4 Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in C4 Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for C4 Therapeutics Inc.

Provide P/S
for C4 Therapeutics Inc.

Provide P/E
for C4 Therapeutics Inc.

Provide P/OCF
for C4 Therapeutics Inc.

Provide P/FCFE
for C4 Therapeutics Inc.

Provide P/B
for C4 Therapeutics Inc.

Provide EV/S
for C4 Therapeutics Inc.

Provide EV/GP
for C4 Therapeutics Inc.

Provide EV/EBITDA
for C4 Therapeutics Inc.

Provide EV/EBIT
for C4 Therapeutics Inc.

Provide EV/OCF
for C4 Therapeutics Inc.

Provide EV/FCFF
for C4 Therapeutics Inc.

Provide EV/IC
for C4 Therapeutics Inc.

Show me price targets
for C4 Therapeutics Inc made by professional analysts.

What are the Revenue projections
for C4 Therapeutics Inc?

How accurate were the past Revenue estimates
for C4 Therapeutics Inc?

What are the Net Income projections
for C4 Therapeutics Inc?

How accurate were the past Net Income estimates
for C4 Therapeutics Inc?

What are the EPS projections
for C4 Therapeutics Inc?

How accurate were the past EPS estimates
for C4 Therapeutics Inc?

What are the EBIT projections
for C4 Therapeutics Inc?

How accurate were the past EBIT estimates
for C4 Therapeutics Inc?

Compare the revenue forecasts
for C4 Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of C4 Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of C4 Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of C4 Therapeutics Inc compared to its peers.

Compare the P/E ratios
of C4 Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing C4 Therapeutics Inc with its peers.

Analyze the financial leverage
of C4 Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for C4 Therapeutics Inc.

Provide ROE
for C4 Therapeutics Inc.

Provide ROA
for C4 Therapeutics Inc.

Provide ROIC
for C4 Therapeutics Inc.

Provide ROCE
for C4 Therapeutics Inc.

Provide Gross Margin
for C4 Therapeutics Inc.

Provide Operating Margin
for C4 Therapeutics Inc.

Provide Net Margin
for C4 Therapeutics Inc.

Provide FCF Margin
for C4 Therapeutics Inc.

Show all solvency ratios
for C4 Therapeutics Inc.

Provide D/E Ratio
for C4 Therapeutics Inc.

Provide D/A Ratio
for C4 Therapeutics Inc.

Provide Interest Coverage Ratio
for C4 Therapeutics Inc.

Provide Altman Z-Score Ratio
for C4 Therapeutics Inc.

Provide Quick Ratio
for C4 Therapeutics Inc.

Provide Current Ratio
for C4 Therapeutics Inc.

Provide Cash Ratio
for C4 Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for C4 Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for C4 Therapeutics Inc?

What is the current Free Cash Flow
of C4 Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for C4 Therapeutics Inc.

Financials

Balance Sheet Decomposition
C4 Therapeutics Inc

Current Assets 271.2m
Cash & Short-Term Investments 253.7m
Receivables 11.8m
Other Current Assets 5.7m
Non-Current Assets 105.3m
Long-Term Investments 28m
PP&E 71.1m
Other Non-Current Assets 6.2m
Current Liabilities 42.8m
Accounts Payable 1.4m
Accrued Liabilities 23.8m
Other Current Liabilities 17.5m
Non-Current Liabilities 87.6m
Other Non-Current Liabilities 87.6m
Efficiency

Earnings Waterfall
C4 Therapeutics Inc

Revenue
20.8m USD
Operating Expenses
-159.8m USD
Operating Income
-139m USD
Other Expenses
6.5m USD
Net Income
-132.5m USD

Free Cash Flow Analysis
C4 Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CCCC Profitability Score
Profitability Due Diligence

C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
21/100
Profitability
Score

C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

CCCC Solvency Score
Solvency Due Diligence

C4 Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
47/100
Solvency
Score

C4 Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CCCC Price Targets Summary
C4 Therapeutics Inc

Wall Street analysts forecast CCCC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CCCC is 18.87 USD with a low forecast of 7.07 USD and a high forecast of 63 USD.

Lowest
Price Target
7.07 USD
2% Upside
Average
Price Target
18.87 USD
173% Upside
Highest
Price Target
63 USD
813% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CCCC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CCCC Price
C4 Therapeutics Inc

1M 1M
-16%
6M 6M
+389%
1Y 1Y
+119%
3Y 3Y
-79%
5Y 5Y
-73%
10Y 10Y
-73%
Annual Price Range
6.9
52w Low
1.18
52w High
11
Price Metrics
Average Annual Return -17.15%
Standard Deviation of Annual Returns 56.15%
Max Drawdown -98%
Shares Statistics
Market Capitalization 473.3m USD
Shares Outstanding 68 600 704
Percentage of Shares Shorted 18.92%

CCCC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

C4 Therapeutics Inc Logo
C4 Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

473.3m USD

Dividend Yield

0%

Description

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

Contact

MASSACHUSETTS
Watertown
490 Arsenal Way, Suite 200
+16172310700.0
https://c4therapeutics.com/

IPO

2020-10-02

Employees

121

Officers

CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
Co-Founder, Independent Director & Member of Scientific Advisory Board
Dr. Kenneth C. Anderson M.D., Ph.D.
Chief Scientific Officer
Dr. Stewart Fisher
Chief Business Officer
Mr. Scott N. Boyle M.B.A., Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Nathanael S. Gray Ph.D.
Chief Financial Officer
Ms. Kendra Adams
Show More
Chief Accounting Officer
Mr. Mark Mossler
Chief Legal Officer & Corporate Secretary
Ms. Jolie M. Siegel J.D.
Chief People Officer
Ms. Kelly A. Schick
Senior Vice President of Strategic Alliances & Business Development
Dr. Isabel Chiu Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CCCC stock?

The intrinsic value of one CCCC stock under the Base Case scenario is 20.71 USD.

Is CCCC stock undervalued or overvalued?

Compared to the current market price of 6.9 USD, C4 Therapeutics Inc is Undervalued by 67%.